Funding
-
Webinar: New Non-dilutive Funding Resource for BioUtah Members
BioUtah has contracted with G2G, Washington DC’s premier consulting firm for non-dilutive funding, to receive a detailed monthly…
-
PPP2 Loans Are Now Open
PPP loans have been reopened with an infusion of $284 billion for First Draw and Second Draw loans.…
-
Request for Proposals – CARES Act Funding in Support of COVID-19 Treatments
August 21, 2020 Update Thank you to everyone who submitted applications for the $2M of CARES Act funding…
-
government & private funding resources for COVID-19 related products, medical technologies and drugs
Government to Growth Government to Growth (G2G) is led by Liz Powell, Esq., MPH, and includes a team…
-
NIH Launches Rapid Acceleration Diagnostics (RADx) Initiative
The National Institutes of Health (NIH) has launched the Rapid Acceleration of Diagnostics (RADx) initiative, aimed at speeding…
-
G2G – One Stop Shopping for Government Grants/Non-Dilutive Funding
Government to Growth (G2G) is led by Liz Powell, Esq., MPH, and includes a team of government affairs…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
